JP2023545497A5 - - Google Patents

Info

Publication number
JP2023545497A5
JP2023545497A5 JP2023522972A JP2023522972A JP2023545497A5 JP 2023545497 A5 JP2023545497 A5 JP 2023545497A5 JP 2023522972 A JP2023522972 A JP 2023522972A JP 2023522972 A JP2023522972 A JP 2023522972A JP 2023545497 A5 JP2023545497 A5 JP 2023545497A5
Authority
JP
Japan
Prior art keywords
sequence
modified
amino acid
seq
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023522972A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023545497A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/055057 external-priority patent/WO2022081890A1/en
Publication of JP2023545497A publication Critical patent/JP2023545497A/ja
Publication of JP2023545497A5 publication Critical patent/JP2023545497A5/ja
Pending legal-status Critical Current

Links

JP2023522972A 2020-10-14 2021-10-14 グリコーゲン貯蔵症1a型を治療するための組成物及び方法 Pending JP2023545497A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063091891P 2020-10-14 2020-10-14
US63/091,891 2020-10-14
US202163248081P 2021-09-24 2021-09-24
US63/248,081 2021-09-24
PCT/US2021/055057 WO2022081890A1 (en) 2020-10-14 2021-10-14 Compositions and methods for treating glycogen storage disease type 1a

Publications (2)

Publication Number Publication Date
JP2023545497A JP2023545497A (ja) 2023-10-30
JP2023545497A5 true JP2023545497A5 (cg-RX-API-DMAC7.html) 2024-10-23

Family

ID=81208619

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023522972A Pending JP2023545497A (ja) 2020-10-14 2021-10-14 グリコーゲン貯蔵症1a型を治療するための組成物及び方法

Country Status (7)

Country Link
US (1) US20230383277A1 (cg-RX-API-DMAC7.html)
EP (1) EP4229195A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023545497A (cg-RX-API-DMAC7.html)
KR (1) KR20230124553A (cg-RX-API-DMAC7.html)
AU (1) AU2021360919A1 (cg-RX-API-DMAC7.html)
CA (1) CA3198671A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022081890A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217942A1 (en) 2018-05-11 2019-11-14 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
EP3850088A4 (en) 2018-09-07 2023-07-19 Beam Therapeutics, Inc. Compositions and methods for improving base editing
KR20210055733A (ko) 2018-09-07 2021-05-17 빔 테라퓨틱스, 인크. 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법
US12600971B2 (en) 2019-02-13 2026-04-14 Beam Therapeutics Inc. Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
WO2020168135A1 (en) 2019-02-13 2020-08-20 Beam Therapeutics Inc. Compositions and methods for treating alpha-1 antitrypsin deficiency
CN114096666B (zh) 2019-02-13 2025-03-18 比姆医疗股份有限公司 治疗血红素病变的组合物和方法
US12594301B2 (en) 2019-09-27 2026-04-07 Beam Therapeutics Inc. Compositions and methods for treatment of liquid cancers
AU2021347359A1 (en) 2020-09-25 2023-05-18 Beam Therapeutics Inc. Fratricide resistant modified immune cells and methods of using the same
WO2025194124A1 (en) * 2024-03-14 2025-09-18 Tessera Therapeutics, Inc. Modified st1cas9 guide nucleic acids
WO2026143185A1 (en) 2024-12-23 2026-07-02 Ensoma Aps Engineered rna-guided dna-binding polypeptides

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102894715B1 (ko) * 2018-08-03 2025-12-03 빔 테라퓨틱스, 인크. 핵산 표적 서열을 변형시키기 위한 다중-이펙터 핵염기 편집기 및 이를 이용하는 방법
EP3850088A4 (en) * 2018-09-07 2023-07-19 Beam Therapeutics, Inc. Compositions and methods for improving base editing
KR20210055733A (ko) * 2018-09-07 2021-05-17 빔 테라퓨틱스, 인크. 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법
WO2020163396A1 (en) * 2019-02-04 2020-08-13 The General Hospital Corporation Adenine dna base editor variants with reduced off-target rna editing
US12600971B2 (en) * 2019-02-13 2026-04-14 Beam Therapeutics Inc. Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
US20220127594A1 (en) * 2019-02-13 2022-04-28 Beam Therapeutics Inc. Compositions and methods for treating glycogen storage disease type 1a
WO2020168135A1 (en) * 2019-02-13 2020-08-20 Beam Therapeutics Inc. Compositions and methods for treating alpha-1 antitrypsin deficiency
KR20240037299A (ko) * 2021-07-23 2024-03-21 빔 테라퓨틱스, 인크. Crispr/cas 편집 시스템용 가이드 rna

Similar Documents

Publication Publication Date Title
US20230026726A1 (en) Crispr/cas-related methods and compositions for treating sickle cell disease
AU2020223733B2 (en) Compositions and methods for the treatment of hemoglobinopathies
US20230018543A1 (en) Crispr/cas-mediated gene conversion
JP2022546608A5 (cg-RX-API-DMAC7.html)
US20210380987A1 (en) Crispr/cas-related methods and compositions for treating cystic fibrosis
JP2026064992A (ja) β異常ヘモグロビン症を治療するためのCRISPR/CAS関連方法および組成物
JP2025170240A5 (cg-RX-API-DMAC7.html)
US20170007679A1 (en) Crispr/cas-related methods and compositions for treating hiv infection and aids
JP2022545950A5 (cg-RX-API-DMAC7.html)
CA3052275A1 (en) Compositions and methods for the treatment of hemoglobinopathies
JP2024534945A (ja) 化学修飾を有するプライム編集のためのガイドrna
WO2015148860A1 (en) Crispr/cas-related methods and compositions for treating beta-thalassemia
AU2020221355A1 (en) Compositions and methods for treating glycogen storage disease type 1a
JP2022532139A5 (cg-RX-API-DMAC7.html)
US20230340468A1 (en) Methods for using guide rnas with chemical modifications
JP2024511621A5 (cg-RX-API-DMAC7.html)
JP2021522825A5 (cg-RX-API-DMAC7.html)
JP2023507034A5 (cg-RX-API-DMAC7.html)